FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Front Vet Sci / Genetic analysis of the equine orthologues for human CYP2D6:...
Frontiers in veterinary science2023; 10; 1188633; doi: 10.3389/fvets.2023.1188633

Genetic analysis of the equine orthologues for human CYP2D6: unraveling the complexity of the CYP2D family in horses.

Abstract: Because of their importance as companion animals or as racehorses, horses can be treated with various drugs. Although it is known that drug withdrawal times can vary for each horse, pharmacogenetics for these animals has not been adequately studied and requires further development. Since is responsible for the metabolism of 25-30% of drugs in humans, including some used to treat horses, a study of the family in horses was conducted to define its genetic structure as well as its expression pattern in the liver. Unassigned: Genomic DNA extracted from venous blood and mRNA from fresh liver tissue were amplified and sequenced to analyze the genomic structure, genotype, and expression of the various enzymes that are part of the equine orthologous family for . Unassigned: Amplification and sequencing of the gDNA of , the major orthologue identified in previous studies, revealed a novel putative genomic structure for this gene compared with that reported from the EquCab3.0 assembly, including the formation of a hybrid structure similar to what happens in human . At the mRNA level, transcripts from six different members of the equine family were detected in horse liver. In addition, genotyping of and revealed the presence of several polymorphisms, six of which result in novel, nonsynonymous amino acid changes for each of the two genes. Unassigned: This study aimed to elucidate the pharmacogenetic analysis of the family in horses and resulted in the identification of a novel gene structure for , the expression of six different members of the family in horse liver, and several novel polymorphisms for and .
Copyright © 2023 Scantamburlo, Nofziger, Paulmichl and Vanoni.
Get Full Text
Publication Date: 2023-10-19 PubMed ID: 37929279PubMed Central: PMC10620600DOI: 10.3389/fvets.2023.1188633Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research focused on investigating the genetic structure and expression pattern of the CYP2D family in horses, which is important in drug metabolism. The study provides new insights into the pharmacogenetics of horses, including the identification of a novel gene structure and several previously unidentified polymorphisms.

Objective and Importance of the Study

  • The study was initiated due to the understanding that horses, often used as race or companion animals, are regularly given various drugs, and their drug withdrawal times can be different for each individual.
  • CYP2D family, known for playing a critical role in the metabolism of 25-30% drugs in humans, is believed to exhibit a similar function in horses, making it a significant genetic feature to study to understand the pharmacogenetics of horses better.

Detailed Procedure of the Study

  • The researchers started by extracting Genomic DNA from venous blood and mRNA from fresh liver tissue of the horses, which was then amplified and sequenced.
  • This process led to the analysis of the genomic structure, different genotypes, and the expression of various enzymes that are part of the equine CYP2D family.

Major Findings

  • Through the amplification and sequencing of the genomic DNA of CYP2D50, an essential orthologue previously identified, a unique putative genomic structure for this gene was discovered, which differs from the previously reported structure from the EquCab3.0 assembly.
  • The novel structure showcased the formation of a hybrid structure, similar to the dynamics observed in human CYP2D6.
  • At the mRNA level, transcripts from six different members of the equine CYP2D family were detected in the horse liver.
  • On genotyping the CYP2D50 and CYP2D54, multiple polymorphisms were found, six of which resulted in new, nonsynonymous amino acid changes for both genes.

Conclusion

  • This research was crucial in providing an in-depth pharmacogenetic analysis of the CYP2D family in horses.
  • It led to the identification of a novel genomic structure for CYP2D50, the expression of six different members of the CYP2D family in horse liver, and several diverse polymorphisms in CYP2D50 and CYP2D54.

Cite This Article

APA
Scantamburlo G, Nofziger C, Paulmichl M, Vanoni S. (2023). Genetic analysis of the equine orthologues for human CYP2D6: unraveling the complexity of the CYP2D family in horses. Front Vet Sci, 10, 1188633. https://doi.org/10.3389/fvets.2023.1188633

Publication

Frontiers in veterinary science
ISSN: 2297-1769
NlmUniqueID: 101666658
Country: Switzerland
Language: English
Volume: 10
Pages: 1188633
PII: 1188633

Researcher Affiliations

Scantamburlo, Giada
  • Pharmgenetix GmbH, Niederalm-Anif, Austria.
Nofziger, Charity
  • Pharmgenetix GmbH, Niederalm-Anif, Austria.
Paulmichl, Markus
  • Privatklinik Maria Hilf GmbH, Klagenfurt, Austria.
Vanoni, Simone
  • Pharmgenetix GmbH, Niederalm-Anif, Austria.

Conflict of Interest Statement

GS, CN and SV are employees of PharmGenetix GmbH. MP is employed by Privatklinik Maria Hilf GmbH.

References

This article includes 46 references
  1. Oates JT, Lopez D. Pharmacogenetics: an important part of drug development with a focus on its application.. Int J Biomed Investig (2018) 1:1–16.
    doi: 10.31531/2581-4745.1000111pmc: PMC7255432pubmed: 32467882google scholar: lookup
  2. Clark JO, Clark TP. Analgesia.. Vet Clin North Am Equine Pract (1999) 15:705–23.
    doi: 10.1016/S0749-0739(17)30140-2pubmed: 10589475google scholar: lookup
  3. Goodrich LR, Nixon AJ. Medical treatment of osteoarthritis in the horse - a review.. Vet J (2006) 171:51–69.
    doi: 10.1016/j.tvjl.2004.07.008pubmed: 16427582google scholar: lookup
  4. Ziegler AL, Blikslager AT. Sparing the gut: COX-2 inhibitors herald a new era for treatment of horses with surgical colic.. Equine Vet Educ (2020) 32:611–6.
    doi: 10.1111/eve.13189pmc: PMC8297937pubmed: 34305336google scholar: lookup
  5. Couetil LL, Cardwell JM, Gerber V, Lavoie JP, Leguillette R, Richard EA. Inflammatory airway disease of horses--revised consensus statement.. J Vet Intern Med (2016) 30:503–15.
    doi: 10.1111/jvim.13824pmc: PMC4913592pubmed: 26806374google scholar: lookup
  6. Mainguy-Seers S, Lavoie JP. Glucocorticoid treatment in horses with asthma: a narrative review.. J Vet Intern Med (2021) 35:2045–57.
    doi: 10.1111/jvim.16189pmc: PMC8295667pubmed: 34085342google scholar: lookup
  7. Haga HA, Lykkjen S, Revold T, Ranheim B. Effect of intratesticular injection of lidocaine on cardiovascular responses to castration in isoflurane-anesthetized stallions.. Am J Vet Res (2006) 67:403–8.
    doi: 10.2460/ajvr.67.3.403pubmed: 16506900google scholar: lookup
  8. Portier KG, Jaillardon L, Leece EA, Walsh CM. Castration of horses under total intravenous anaesthesia: analgesic effects of lidocaine.. Vet Anaesth Analg (2009) 36:173–9.
    doi: 10.1111/j.1467-2995.2008.00445.xpubmed: 19239656google scholar: lookup
  9. Matsuda Y, Hobo S, Naito H. Transferability of cephalothin to the alveolar cavity in thoroughbreds.. J Vet Med Sci (1999) 61:209–12.
    doi: 10.1292/jvms.61.209pubmed: 10331190google scholar: lookup
  10. Valverde A. Alpha-2 agonists as pain therapy in horses.. Vet Clin North Am Equine Pract (2010) 26:515–32.
    doi: 10.1016/j.cveq.2010.07.003pubmed: 21056297google scholar: lookup
  11. Giguere S, Burton AJ, Berghaus LJ, Haspel AD. Comparative pharmacokinetics of minocycline in foals and adult horses.. J Vet Pharmacol Ther (2017) 40:335–41.
    doi: 10.1111/jvp.12366pubmed: 27682322google scholar: lookup
  12. Patel T, Magdesian KG, Estell KE, Edman JM, Knych HK. Pharmacokinetics of chloramphenicol base in horses and comparison to compounded formulations.. J Vet Pharmacol Ther (2019) 42:609–16.
    doi: 10.1111/jvp.12777pubmed: 31162675google scholar: lookup
  13. Chapuis RJJ, Smith JS, Uehlinger FD, Meachem M, Johnson R, Dowling PM. Pharmacokinetics and pharmacodynamics of doxycycline in a Streptococcusequi subsp. zooepidemicus infection model in horses.. J Vet Pharmacol Ther (2021) 44:766–75.
    doi: 10.1111/jvp.12982pubmed: 34057219google scholar: lookup
  14. Baggot JD. The pharmacological basis of cardiac drug selection for use in horses.. Equine Vet J Suppl (1995) 27:97–100.
    doi: 10.1111/j.2042-3306.1995.tb04995.xpubmed: 8933075google scholar: lookup
  15. Ballester MR, Roig E, Gich I, Puntes M, Delgadillo J, Santos B. Randomized, open-label, blinded-endpoint, crossover, single-dose study to compare the pharmacodynamics of torasemide-PR 10 mg, torasemide-IR 10 mg, and furosemide-IR 40 mg, in patients with chronic heart failure.. Drug Des Devel Ther (2015) 9:4291–302.
    doi: 10.2147/DDDT.S86300pmc: PMC4532344pubmed: 26273191google scholar: lookup
  16. Agne GF, Jung SW, Wooldridge AA, Duran SH, Ravis W, Toribio R. Pharmacokinetic and pharmacodynamic properties of orally administered torsemide in healthy horses.. J Vet Intern Med (2018) 32:1428–35.
    doi: 10.1111/jvim.15213pmc: PMC6060311pubmed: 29770976google scholar: lookup
  17. Andrews FM, Sifferman RL, Bernard W, Hughes FE, Holste JE, Daurio CP. Efficacy of omeprazole paste in the treatment and prevention of gastric ulcers in horses.. Equine Vet J Suppl (1999) 31:81–6.
    doi: 10.1111/j.2042-3306.1999.tb05176.xpubmed: 10696301google scholar: lookup
  18. Videla R, Sommardahl CS, Elliott SB, Vasili A, Andrews FM. Effects of intravenously administered esomeprazole sodium on gastric juice pH in adult female horses.. J Vet Intern Med (2011) 25:558–62.
    doi: 10.1111/j.1939-1676.2011.0716.xpubmed: 21457324google scholar: lookup
  19. Internationale F-FE. FEI list of detection times 2022 [updated 2022.. (2022).
  20. Tobin T, Dirikolu L, Brewer K, Hughes CG. A clinician's guide to factors affecting withdrawal times for equine therapeutic medications.. Vet J (2013) 198:313–21.
    doi: 10.1016/j.tvjl.2013.07.002pubmed: 23932745google scholar: lookup
  21. Waller P, Lomnicka I, Lucas C, Johnson S, Dirikolu L. The medication violations in racehorses at Louisiana racetracks from 2016 to 2020.. Vet Med Sci (2022) 8:553–60.
    doi: 10.1002/vms3.724pmc: PMC8959255pubmed: 34989156google scholar: lookup
  22. Internationale F-FE. Protecting the EU equine industry and equine health adn welfare 2021. (2021).
  23. Nebert DW, Russell DW. Clinical importance of the cytochromes P450.. Lancet (2002) 360:1155–62.
    doi: 10.1016/S0140-6736(02)11203-7pubmed: 12387968google scholar: lookup
  24. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity.. Pharmacogenomics J (2005) 5:6–13.
    doi: 10.1038/sj.tpj.6500285pubmed: 15492763google scholar: lookup
  25. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.. Pharmacol Ther (2007) 116:496–526.
    doi: 10.1016/j.pharmthera.2007.09.004pubmed: 18001838google scholar: lookup
  26. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.. Pharmacol Ther (2013) 138:103–41.
    doi: 10.1016/j.pharmthera.2012.12.007pubmed: 23333322google scholar: lookup
  27. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.. Mol Psychiatry (2004) 9:442–73.
    doi: 10.1038/sj.mp.4001494pubmed: 15037866google scholar: lookup
  28. Corado CR, McKemie DS, Knych HK. Dextromethorphan and debrisoquine metabolism and polymorphism of the gene for cytochrome P450 isozyme 2D50 in thoroughbreds.. Am J Vet Res (2016) 77:1029–35.
    doi: 10.2460/ajvr.77.9.1029pubmed: 27580115google scholar: lookup
  29. Gretler SR, Finno CJ, Kass PH, Knych HK. Functional phenotyping of the CYP2D6 probe drug codeine in the horse.. BMC Vet Res (2021) 17:77.
    doi: 10.1186/s12917-021-02788-ypmc: PMC7881596pubmed: 33581736google scholar: lookup
  30. Rendon RA, Shuster L, Dodman NH. The effect of the NMDA receptor blocker, dextromethorphan, on cribbing in horses.. Pharmacol Biochem Behav (2001) 68:49–51.
    doi: 10.1016/S0091-3057(00)00437-8pubmed: 11274707google scholar: lookup
  31. Westermann CM, Laan TT, van Nieuwstadt RA, Bull S, Fink-Gremmels J. Effects of antitussive agents administered before bronchoalveolar lavage in horses.. Am J Vet Res (2005) 66:1420–4.
    doi: 10.2460/ajvr.2005.66.1420pubmed: 16173487google scholar: lookup
  32. Cox S, Villarino N, Doherty T. Determination of oral tramadol pharmacokinetics in horses.. Res Vet Sci (2010) 89:236–41.
    doi: 10.1016/j.rvsc.2010.02.011pubmed: 20223494google scholar: lookup
  33. Knych HK, Stucker K, Gretler SR, Kass PH, McKemie DS. Pharmacokinetics, adverse effects and effects on thermal nociception following administration of three doses of codeine to horses.. BMC Vet Res (2022) 18:196.
    doi: 10.1186/s12917-022-03299-0pmc: PMC9131543pubmed: 35614473google scholar: lookup
  34. Camargo FCH C, Lehner AF, Tobin T. Trace level benzoylecgonine identifications in post-race urines: probable sources and the regulatory significance of such identifications.. AAEP Proceedings (2006) 52:331–6.
  35. Camargo FCL AF, Karpiesiuk W, Stirling K, Kavanagh PV, Brennan N, Dowling M. Rewiew of environmental morphine identifications: worldwide occurrences and responses of authoriites.. AAEP Proceedings (2005) 61:58–64.
  36. Campos-Manas MC, Ferrer I, Thurman EM, Sanchez Perez JA, Aguera A. Identification of opioids in surface and wastewaters by LC/QTOF-MS using retrospective data analysis.. Sci Total Environ (2019) 664:874–84.
    doi: 10.1016/j.scitotenv.2019.01.389pubmed: 30769311google scholar: lookup
  37. Corado CR, McKemie DS, Young A, Knych HK. Evidence for polymorphism in the cytochrome P450 2D50 gene in horses.. J Vet Pharmacol Ther (2016) 39:245–54.
    doi: 10.1111/jvp.12269pubmed: 26441153google scholar: lookup
  38. Yasukochi Y, Satta Y. Evolution of the CYP2D gene cluster in humans and four non-human primates.. Genes Genet Syst (2011) 86:109–16.
    doi: 10.1266/ggs.86.109pubmed: 21670550google scholar: lookup
  39. Knych HK, Baden RW, Gretler SR, McKemie DS. Characterization of the in vitro CYP450 mediated metabolism of the polymorphic CYP2D6 probe drug codeine in horses.. Biochem Pharmacol (2019) 168:184–92.
    doi: 10.1016/j.bcp.2019.07.005pubmed: 31295464google scholar: lookup
  40. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions.. Genome Res (2001) 11:863–74.
    doi: 10.1101/gr.176601pmc: PMC311071pubmed: 11337480google scholar: lookup
  41. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm.. Nat Protoc (2009) 4:1073–81.
    doi: 10.1038/nprot.2009.86pubmed: 19561590google scholar: lookup
  42. Choi Y, Chan AP. PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels.. Bioinformatics (2015) 31:2745–7.
    doi: 10.1093/bioinformatics/btv195pmc: PMC4528627pubmed: 25851949google scholar: lookup
  43. Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional effect of amino acid substitutions and indels.. PLoS One (2012) 7:e46688.
    doi: 10.1371/journal.pone.0046688pmc: PMC3466303pubmed: 23056405google scholar: lookup
  44. Gaedigk A, Bradford LD, Alander SW, Leeder JS. CYP2D6*36 gene arrangements within the cyp2d6 locus: association of CYP2D6*36 with poor metabolizer status.. Drug Metab Dispos (2006) 34:563–9.
    doi: 10.1124/dmd.105.008292pubmed: 16415111google scholar: lookup
  45. Ghosh S, Qu Z, Das PJ, Fang E, Juras R, Cothran EG. Copy number variation in the horse genome.. PLoS Genet (2014) 10:e1004712.
    doi: 10.1371/journal.pgen.1004712pmc: PMC4207638pubmed: 25340504google scholar: lookup
  46. Valsesia A, Stevenson BJ, Waterworth D, Mooser V, Vollenweider P, Waeber G. Identification and validation of copy number variants using SNP genotyping arrays from a large clinical cohort.. BMC Genomics (2012) 13:241.
    doi: 10.1186/1471-2164-13-241pmc: PMC3464625pubmed: 22702538google scholar: lookup

Citations

This article has been cited 0 times.
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.